Jane Street
CRNX icon

Jane Street’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jane Street’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$469K Buy
12,900
+2,500
+24% +$112K ﹤0.01% 8213
2025
Q4 		$484K Sell
10,400
-118,700
-92% -$5.28M ﹤0.01% 7757
2025
Q3 		$5.38M Buy
+129,100
New +$4.13M ﹤0.01% 3320
2025
Q2 		– Sell
-21,600
Closed -$724K – 9785
2025
Q1 		$724K Buy
+21,600
New +$807K ﹤0.01% 6176
2024
Q3 		– Sell
-15,300
Closed -$685K – 9662
2024
Q2 		$685K Buy
15,300
+2,800
+22% +$129K ﹤0.01% 6491
2024
Q1 		$585K Sell
12,500
-14,900
-54% -$583K ﹤0.01% 6377
2023
Q4 		$975K Sell
27,400
-28,700
-51% -$880K ﹤0.01% 5609
2023
Q3 		$1.67M Buy
+56,100
New +$1.16M ﹤0.01% 4343

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jane Street's CRNX Position: Q4 2025 in Review

Jane Street sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 13,982 shares — an estimated $622K sold.

Jane Street first reported a position in CRNX in Q2 2020 and held it in 11 quarters. The position peaked at $6.62M in Q3 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Jane Street reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 13,982 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $622K.
  • Jane Street first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 11 quarters.
  • Jane Street's Crinetics Pharmaceuticals position peaked at $6.62M in Q3 2024.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.